#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

ORLANDO, FL, USA (UroToday.com) - Corticosteriods are administered in combination with abiratirone to compensate for loss of steroid hormone production as a result of CYP17A1 inhibition. Long-term use of prednisone in this patient population has not be studied and may be associated with adverse events. Karim Fizazi, MD, PhD and colleagues studied 2 267 patients with mCRPC from the COU-AA-301 and COU-AA-302 trials to determine how frequently each of several steroid-associated adverse events occurred from the databases.

gucancerssympaltThe overall incidence of adverse events was 25%, 26%, and 23% for all patients, abiraterone + prednisone, or prednisone alone, respectively. The incidence of grade ≥ 3 adverse events was 5%, 5%, and 4% for all patients, abiraterone + prednisone, or prednisone alone, respectively. The most common grade ≥ 3 events were hyperglycemia (2%), cataract (0.4%), diabetes mellitus (0.4%), gastrointestinal hemorrhage (0.3%), adrenal insufficiency (0.1%), hip fracture (0.1%), melena (0.1%), and spinal osteoporotic compression fracture (0.1%).

The authors conclude that prednisone given with or without abiraterone is associated with an overall low incidence of steroid-associated adverse events.

Presented by Karim Fizazi, MD, PhD at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

Institut Gustave Roussy, Villejuif, France

Reported by Phillip Abbosh, MD, PhD, medical writer for UroToday.com